← Leaderboards
Cornelia L Trimble
Johns Hopkins University
$7,319,162
Attributed
$9,015,966
Total exposure
10
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $805.4K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$9,015,966 · 10
By mechanism
P50$4,959,386 · 4
R21$2,041,327 · 4
R01$1,334,626 · 1
K23$680,627 · 1
Top collaborators
- T.-C. Wu10 shared
- Ronald D. Alvarez5 shared
- Drew M. Pardoll5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Thomas W Kensler$20,869,769
- David P Goldberg$10,366,521
- Richard Bruce Roden$11,133,737
- Rajini Rao$27,662,029
- Mary E McCaul$21,975,059
Others in their field
Top investigators on “Human Papillomavirus”
- Ronald T Mitsuyasu · University Of California Los Angeles$106,431,894
- Leonard Freedman · Leidos Biomedical Research, Inc.$53,948,093
- Kathryn M Anastos · Montefiore Medical Center (Bronx, Ny)$50,130,116
- Paula Gonzalez-Maya · Fundacion Inciensa$38,145,031
- David Heimbrook · Leidos Biomedical Research, Inc.$33,306,253
- Paul F Lambert · University Of Wisconsin Madison$31,091,618
Research focus
Human PapillomavirusImmune ResponseMalignant Neoplasm Of Cervix UteriResearch PersonnelImmunologicsVaccinationCellsImmuneResponseLesionMediatingSpecimenPeripheral BloodT-LymphocyteSiteHuman Papillomavirus 16CervicalCohortAntigensProgramsEnrollmentBaseExcisionClinical Trials
Grant awards (39)
Immunomodulatory effects of topical artesunate on cervical intraepithelial neoplasia 2/3.$187,556
R21 · FY2023 · CA · contact PI
Immunomodulatory effects of topical artesunate on cervical intraepithelial neoplasia 2/3.$229,659
R21 · FY2022 · CA · contact PI
Tissue/Pathology & Immunology Core$261,284
P50 · FY2018 · CA · contact PI
Molecular Attributes of Tissue Immune Response in HPV Disease$231,123
P50 · FY2018 · CA · contact PI
Tissue/Pathology & Immunology Core$267,092
P50 · FY2017 · CA · contact PI
Molecular Attributes of Tissue Immune Response in HPV Disease$236,111
P50 · FY2017 · CA · contact PI
Tissue/Pathology & Immunology Core$249,976
P50 · FY2016 · CA · contact PI
Molecular Attributes of Tissue Immune Response in HPV Disease$221,006
P50 · FY2016 · CA · contact PI
Tissue/Pathology & Immunology Core$252,518
P50 · FY2015 · CA · contact PI
Molecular Attributes of Tissue Immune Response in HPV Disease$223,257
P50 · FY2015 · CA · contact PI
Tissue/Pathology & Immunology Core$250,556
P50 · FY2014 · CA · contact PI
Mechanisms of mucosal immune evasion in high grade cervical dysplasia$245,164
R01 · FY2014 · CA · contact PI
Molecular Attributes of Tissue Immune Response in HPV Disease$221,257
P50 · FY2014 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$288,750
P50 · FY2013 · CA
Mechanisms of mucosal immune evasion in high grade cervical dysplasia$250,684
R01 · FY2013 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$193,870
P50 · FY2013 · CA · contact PI
Mechanisms of mucosal immune evasion in high grade cervical dysplasia$13,569
R01 · FY2013 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$309,265
P50 · FY2012 · CA
Mechanisms of mucosal immune evasion in high grade cervical dysplasia$266,635
R01 · FY2012 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$210,399
P50 · FY2012 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$305,192
P50 · FY2011 · CA
Mechanisms of mucosal immune evasion in high grade cervical dysplasia$267,212
R01 · FY2011 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$208,423
P50 · FY2011 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$301,914
P50 · FY2010 · CA
Mechanisms of mucosal immune evasion in high grade cervical dysplasia$291,362
R01 · FY2010 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$210,262
P50 · FY2010 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$304,161
P50 · FY2009 · CA
Therapeutic HPV vaccination for stage IB1 cervical cancer$288,306
R21 · FY2009 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$212,970
P50 · FY2009 · CA · contact PI
Therapeutic HPV vaccination for stage IB1 cervical cancer$294,156
R21 · FY2008 · CA · contact PI
Therapeutic DNA-MVA prime boost vaccination for HPV disease$214,492
R21 · FY2007 · CA · contact PI
Therapeutic DNA-MVA prime boost vaccination for HPV disease$221,158
R21 · FY2006 · CA · contact PI
THERAPEUTIC VACCINES FOR HPV DISEASES$136,728
K23 · FY2005 · CA
A Phase I/II Trial of a Therapeutic HPV Vaccine$305,000
R21 · FY2004 · CA
THERAPEUTIC VACCINES FOR HPV DISEASES$136,728
K23 · FY2004 · CA
A Phase I/II Trial of a Therapeutic HPV Vaccine$301,000
R21 · FY2003 · CA
THERAPEUTIC VACCINES FOR HPV DISEASES$136,728
K23 · FY2003 · CA
THERAPEUTIC VACCINES FOR HPV DISEASES$135,555
K23 · FY2002 · CA
THERAPEUTIC VACCINES FOR HPV DISEASES$134,888
K23 · FY2001 · CA